-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $110

Benzinga·10/28/2026 13:27:37
Listen to the news
Wells Fargo analyst Yanan Zhu maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Overweight and raises the price target from $87 to $110.